fb825
mAbexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02309762)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSYO4XL7781V ↗
- ChEMBLCHEMBL4297952 ↗
Also known as
- fb825
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06397911 | Phase 2 | Aug 8, 2024 | National Taiwan University |
| NCT05952986 | Phase 1 | May 3, 2023 | — |
| NCT05008965 | Phase 2 | Jul 27, 2021 | Microbio Co Ltd, Oneness Biotech Co., Ltd. |
| NCT04413942 | Phase 2 | Mar 10, 2020 | Forest Hills Dermatology Group, Oneness Biotech Co., Ltd. |
| NCT05059509 | Phase 2 | Feb 6, 2020 | Oneness Biotech Co., Ltd. |
| NCT03758716 | Phase 2 | Jul 3, 2017 | Microbio Co Ltd, National Taiwan University |
| NCT02309762 | Phase 1 | Mar 1, 2015 | Microbio Co Ltd |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Microbio Co Ltd | For profit | 3 | 2 | 2 | 2015 |
| Oneness Biotech Co., Ltd. | For profit | 3 | 3 | 1 | 2020 |
| National Taiwan University | Academic/Hospital | 2 | 0 | 1 | 2017 |
| Forest Hills Dermatology Group | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1